NCT00247559

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 221 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, the number of randomised, controlled clinical trials is small. Much of the published information is based on open-label studies or anecdotal data. Of the robust trial data that is available, the vast majority relates to the treatment of glabellar lines, and there is little data available regarding the use of BoNT-A in lateral canthal lines. This study aims to determine the optimum dose for the use of BoNT-A in this area.

Conditions

• Lateral Canthal Lines

Interventions

Type	Name	Description
BIOLOGICAL	Botulinum toxin type A

Timeline

• Start date: 2004-05-01
• Primary completion: 2005-04-08
• Completion: 2005-04-08
• First posted: 2005-11-02
• Last updated: 2019-11-22

Locations

9 sites across 3 countries: France, Germany, United Kingdom